It's irrelevant whether it works or not. You can spend close to a billion dollars developing a drug but what's the point if there is already a cure that will be available for a few hundred dollars by the time you commercialise it. I'm glad they are not pursuing this further as they need the money to progress HVB and AMD, both indications have no cure and this is where the money needs to go.
Are there any other biotechs we know of whose market cap is half their cash backing?
- Forums
- ASX - By Stock
- BLT
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-16
-
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online